期刊文献+

Recent Progress and Future Direction for the Application of Multiomics Data in Clinical Liver Transplantation

原文传递
导出
摘要 Omics data address key issues in liver transplantation(LT)as the most effective therapeutic means for end-stage liver disease.The purpose of this study was to review the current application and future direction for omics in LT.We reviewed the use of multiomics to elucidate the pathogenesis leading to LT and prognostication.Future directions with respect to the use of omics in LT are also described based on perspectives of surgeons with experience in omics.Significant molecules were identified and summarized based on omics,with a focus on post-transplant liver fibrosis,early allograft dysfunction,tumor recurrence,and graft failure.We emphasized the importance omics for clinicians who perform LTs and prioritized the directions that should be established.We also outlined the ideal workflow for omics in LT.In step with advances in technology,the quality of omics data can be guaranteed using an improved algorithm at a lower price.Concerns should be addressed on the translational value of omics for better therapeutic effects in patients undergoing LT.
出处 《Journal of Clinical and Translational Hepatology》 SCIE 2022年第2期363-373,共11页 临床与转化肝病杂志(英文版)
基金 supported by Innovative Research Groups of National Natural Science Foundation of China(81721091) Major Program of National Natural Science Foundation of China(91542205) National S&T Major Project(2017ZX 10203205) National Natural Science Foundation of China(81902813) Zhejiang International Science and Technology Cooperation Project(2016C04003) Zhejiang Provincial Natural Science Foundation of China(LY18H030002) Zhejiang Medical Association(grant no.2019ZYC-A81) International Youth Exchange Programme by China Association for Science and Technology(2019),Tianqing Liver Diseases Research Fund(TQGB20200114) Medical Health Science and Technology Project of Zhejiang Provincial Health Commission(2021KY145) Organ Transplantation Overseas Training for Youth Talents from Shulan Excellent Talent Project,CSCO(Chinese Society Of Clinical Oncology)-Bayer Tumor Research Funding(Y-bayer202001/zb-0003) Open Fund of Key laboratory of High-Incidence-Tumor Prevention&Treatment(Guangxi Medical University)belonged to Ministry of Education.
  • 相关文献

参考文献4

二级参考文献8

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部